IMAHealthcare · BiotechnologyIMA Stock Forecast: ImageneBio, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering ImageneBio, Inc. hold a median 12-month price target of $13 — +130.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
IMA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores ImageneBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (79): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own ImageneBio, Inc. — and when they’d sell — is the membership.
IMA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +130.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 May 2026 | Wedbush | Reiterates | Underperform | $2.00 |
| 25 Nov 2025 | Wedbush | Assumes | Underperform | $2.00 |
| 24 Oct 2025 | Leerink Partners | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IMA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
ImageneBio, Inc. (IMA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.6×
- Price / sales
- 78.8×
- Price / book
- 0.5×
- EV / EBITDA
- 1.0×
Cheaper than 80% of US stocks
Cheaper than 4% of US stocks
Cheaper than 84% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −6056.4%
- Net margin
- 0.0%
Higher than 3% of US stocks
Higher than 30% of US stocks
- Return on equity
- −86.2%
- Return on assets
- −45.6%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IMA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMA appears on the weeks it earns a place.
Frequently asked questions about IMA stock
What is the IMA stock price forecast for 2026-2027?
The 3 Wall Street analysts covering ImageneBio, Inc. have a median 12-month price target of $13, with estimates ranging from $2 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMA stock a buy right now?
Of the 3 analysts covering ImageneBio, Inc., 2 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ImageneBio, Inc. 16 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMA?
As at 1 Aug 2026, ImageneBio, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).
Will IMA stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +130.5% from the last close, and Ticker Nerd's factor model ranks ImageneBio, Inc. 16 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMA stock forecast for 2030?
No analyst covering ImageneBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $24 over the next 12 months.
How has IMA stock performed over the past year?
ImageneBio, Inc. returned -67.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ImageneBio, Inc. do?
ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for immunological, autoimmune, and inflammatory diseases.
About ImageneBio, Inc.
ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutics for immunological, autoimmune, and inflammatory diseases. The company is driven by the mission to transform patient outcomes through innovative medicines that aim to not only control symptoms but also alter the course of serious immune-related conditions. Leveraging both external innovation and its proprietary QuadraTek® platform, ImageneBio is focused on creating differentiated therapies with optimized safety, efficacy, and convenience profiles. Its lead product candidate, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that has progressed through Phase 2a clinical trials targeting atopic dermatitis and alopecia areata. The company's research and development pipeline is engineered to address a broad spectrum of immune and inflammatory indications, supporting its goal to pioneer next-generation treatments for underserved patient populations. Founded in 2016 and headquartered in San Diego, ImageneBio plays a significant role in the biotechnology sector by striving to improve quality of life for those affected by chronic immunological and inflammatory diseases.
CEO Dr. Kristin Yarema Ph.D. · 17 employees · United States · https://www.inmagenebio.com